PURPOSE: A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy. METHODS AND MATERIALS: Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply 0.1% MMF or placebo cream daily. The primary study endpoint was the provider-assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider-assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient-reported outcome measures included the Skindex-16, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality-of-life self-assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy. RESULTS: A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider-assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for MMF vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient-reported outcome measures, the maximum Skindex-16 score for the MMF group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group's maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002). CONCLUSION: Patients receiving daily MMF during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.
RCT Entities:
PURPOSE: A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy. METHODS AND MATERIALS: Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply 0.1% MMF or placebo cream daily. The primary study endpoint was the provider-assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider-assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient-reported outcome measures included the Skindex-16, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality-of-life self-assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy. RESULTS: A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider-assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for MMF vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient-reported outcome measures, the maximum Skindex-16 score for the MMF group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group's maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002). CONCLUSION:Patients receiving daily MMF during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.
Authors: Sue Heggie; Guy P Bryant; Lee Tripcony; Jacqui Keller; Pauline Rose; Mary Glendenning; Jenny Heath Journal: Cancer Nurs Date: 2002-12 Impact factor: 2.592
Authors: M Schmuth; M A Wimmer; S Hofer; A Sztankay; G Weinlich; D M Linder; P M Elias; P O Fritsch; E Fritsch Journal: Br J Dermatol Date: 2002-06 Impact factor: 9.302
Authors: Rebecca K S Wong; René-Jean Bensadoun; Christine B Boers-Doets; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Mario E Lacouture Journal: Support Care Cancer Date: 2013-08-14 Impact factor: 3.603
Authors: Pamela J Atherton; Kelli N Burger; Charles L Loprinzi; Michelle A Neben Wittich; Robert C Miller; Aminah Jatoi; Jeff A Sloan Journal: Support Care Cancer Date: 2011-09-16 Impact factor: 3.603
Authors: Jennifer J Hu; Tengjiao Cui; Jorge L Rodriguez-Gil; Glenn O Allen; Jie Li; Cristiane Takita; Brian E Lally Journal: Radiat Environ Biophys Date: 2014-05-05 Impact factor: 1.925
Authors: Mimi R Borrelli; Abra H Shen; Gordon K Lee; Arash Momeni; Michael T Longaker; Derrick C Wan Journal: Ann Plast Surg Date: 2019-10 Impact factor: 1.539
Authors: Michelle A Neben-Wittich; Pamela J Atherton; David J Schwartz; Jeff A Sloan; Patricia C Griffin; Richard L Deming; Jon C Anders; Charles L Loprinzi; Kelli N Burger; James A Martenson; Robert C Miller Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Sandrine Censabella; Stefan Claes; Jolien Robijns; Paul Bulens; Jeroen Mebis Journal: Support Care Cancer Date: 2016-04-26 Impact factor: 3.603